FRIDAY, Jan. 16, 2026 -- Population-based estimated glomerular filtration rate (eGFR) charts may be beneficial for early identification and prevention of chronic kidney disease , according to a study published online Jan. 16 in Kidney International . Yuanhang Yang, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a population-based observational cohort study involving 1,179,501 unique adults aged 40 to 100 years with 6,914,993 repeated annual eGFR measurements. The as

IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 35 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on January 20, 2026 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis

iStock, Olena Koliesnik Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is underway, with data expected this quarter. Rumors of a potential takeover by Sanofi have drummed up market interest in Ocular Therapeutix, sending shares of the Massachusetts-based biotech surging early Thursday morning. The rumors were first reported by French publication La Lettre , which on Thursday said the pharma had initially approached Ocular

FRIDAY, Jan. 16, 2026 — Ever felt drunk, hammered, wasted, absolutely smashed — but you haven’t touched a drop of alcohol? You might have suffered from a rare gut condition called auto-brewery syndrome, which causes alcohol intoxication in people who haven’t had anything to drink. Researchers now think they’ve figured out the specific way auto-brewery syndrome plays out in people’s bodies, they report in the journal Nature Microbiology . Certain species of gut bacteria appear to drive auto-brew

FRIDAY, Jan. 16, 2026 -- Low dietary lycopene intake is associated with an increased risk for severe periodontitis , according to a study published in the February issue of the Journal of Nutrition, Health & Aging . Katherine Kwong, Ph.D., from Connecticut College in New London, and colleagues investigated the association between insufficient lycopene intake and the risk for periodontitis among older adults. The analysis included 1,227 adults (aged 65 to 79 years) participating in the National H

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope AMR is a leading cause of kidney transplant loss with no approved treatments U.S. IND previously approved by FDA for Phase 1 AMR study SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 15, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38 monoclonal antibody, for patients with organ tran

iStock, Man As Thep Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets. Novo Nordisk’s business development team had 200 meetings at the J.P. Morgan Healthcare Conference, a staggering figure as the Danish pharma tries to get back into the game after a messy bidding war over Metsera in the fall. “[Metsera] was a company that was very interesting to us and very complimen

Calgary, Alberta--(News - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, announces the successful completion of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA). H

· Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN · Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN for patients 12 years and older Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomeruloneph

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancers NOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T cells against neoantigens present in tumors and precancer lesions in LS carriers Publication in Nature Medicine underscores significance of NOUS-209 clinical data and its innovative approach to intercept cancer before it develops Data support advancing NOUS-209 into FDA- and EMA-aligned registra